Research Papers:

Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis

Jing Zhang _, Jiaming Liu, Chenjing Zhu, Jialing He, Jinna Chen, Yunliu Liang, Feng Yang, Xin Wu, Xuelei Ma

PDF |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:24797-24803. https://doi.org/10.18632/oncotarget.15044

Metrics: PDF 599 views  |   HTML 244 views  |   ?  


Jing Zhang1,2,*, Jiaming Liu1,3,*, Chenjing Zhu1,*, Jialing He1, Jinna Chen1, Yunliu Liang1, Feng Yang1, Xin Wu1, Xuelei Ma1,*

1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China

2Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, PR China

3Department of Urology, Institute of Urology, Laboratory of Reconstructive Urology, West China Hospital, Sichuan University, Chengdu 610041, PR China

*These authors have contributed equally to this work

Correspondence to:

Xuelei Ma, email: drmaxuelei@gmail.com

Keywords: VEGF, cervical cancer, prognosis

Received: October 31, 2016    Accepted: January 04, 2017    Published: February 03, 2017


The prognostic role of vascular endothelial growth factor (VEGF) in cervical cancer is controversial to date. The aim of this study was to evaluate the prognostic value of VEGF and VEGF-C in patients with cervical cancer. Relevant studies were identified by systematic search of the PubMed and Embase database. The primary data of eligible studies was hazard ratio (HR) with 95% confidence interval (95% CI) of survival outcomes, including overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). Pooled HR (95% CI) was calculated to evaluate the prognostic role of VEGF and VEGF-C in cervical cancer patients. The methodological qualities of the included studies were assessed using REMARK. Fourteen eligible articles including 1306 patients were included in the meta-analysis. The pooled HRs (95% CIs) of VEGF for OS and DFS/PFS were 2.29 [1.27, 4.14] and 2.77 [1.37, 5.62], respectively. The HR (95% CI) of VEGF-C for OS was 3.94 [2.22, 6.99]. This meta-analysis suggested that high expressions of VEGF and VEGF-C were significantly associated with poor survival outcome in cervical cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15044